Background: Despite abciximab (ReoPro짰)-coated stent has inhibitory effect on coronary artery restenosis, long term clinical outcome is unknown. Methods: This study was a prospective, randomized trial to compare the effects of abciximab-coated stent, which was implanted for 95 patients, with those of control stent, which was implanted for 93 patients for de novo coronary lesions. We evaluated the major adverse cardiac events (MACE) at two-year follow-up. Results: Although there were no significant differences in the incidences of cardiac death (0% vs. 1.1%, p=0.3) and target vessel revascularization (16% vs. 21%, p=0.4) between both groups, there were trends toward lower incidences of non-fatal myocardial infarction (0% vs. 2.3%, p=0.16) and total MACE (16% vs. 24%, p=0.19) in abciximab-coated stent group compared with control stent group. Moreover, stent thrombosis did not occur in abciximab-coated stent group. Six month intravascular ultrasound analysis showed that an increase of neointimal hyperplasia area was significantly smaller in abciximab-coated stent group compared with control stent group (2.0짹1.6 mm2 vs. 3.4짹1.7 mm2, p=0.001). Conclusions: There is a trend that abciximab-coated stents inhibit neointimal hyperplasia and had lower total MACE and no stent thrombosis at two-year follow-up.